MedTrace Logo

Gastric Volumes by US in Term Parturients Undergoing CS With and Without Metoclopramide

NCT05033041 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2025-09-11

Study results available
· View outcomes & findings →

Summary

Our objective is to compare gastric volumes (mL) between women who receive metoclopramide versus placebo prior to scheduled cesarean delivery in appropriately fasted patients. If metoclopramide is found not to reduce gastric volumes this would inform future practice guidelines for obstetric anesthesia, which currently recommends metoclopramide administration prior to cesarean deliveries.

We hypothesize that metoclopramide given to women with appropriate fasting prior to cesarean delivery does not result in any clinically significant reduction in gastric volume (mL) and therefore does not provide any additional benefit for aspiration prophylaxis but may expose patients to unnecessary side effects. A secondary objective will be to evaluate if gastric volume is a significant predictor of intraoperative nausea and vomiting.

Conditions

  • Pregnancy
  • Cesarean Section
  • Aspiration

Interventions

DRUG

Study drug metoclopramide

Intravenous administration of 10 mg metoclopramide

DRUG

Study drug placebo administration

Intravenous administration of placebo (sterile normal saline)

Sponsors & Collaborators

Principal Investigators

  • Jennifer Banayan, MD · Northwestern University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-20
Primary Completion
2024-01-30
Completion
2024-02-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05033041 on ClinicalTrials.gov